Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as zelicapavir (therapeutic dose)
zelicapavir · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| zelicapavir | EXPERIMENTAL | zelicapavir, oral suspension, once daily for 7 days |
| Placebo | PLACEBO_COMPARATOR | Matching placebo, orally, once daily for 7 days |
| zelicapavir Dose 1 (therapeutic dose) | EXPERIMENTAL | All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25. |
| zelicapavir Dose 2 (supratherapeutic dose) | EXPERIMENTAL | All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25. |
| moxifloxacin | EXPERIMENTAL | All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25. |
| Name | Type | Description |
|---|---|---|
| zelicapavir | DRUG | Oral suspension |
| Placebo | DRUG | Placebo oral suspension to match zelicapavir |
| zelicapavir (therapeutic dose) | DRUG | Subjects will receive zelicapavir (TD) once per treatment period. |
| zelicapavir (supratherapeutic dose) | DRUG | Subjects will receive zelicapavir (SD) once per treatment period. |
| moxifloxacin | DRUG | Subjects will receive moxifloxin once per treatment period. |
Inclusion Criteria: * Participants diagnosed with RSV infection using an approved diagnostic assay, without known and/or documented coinfection with SARS-CoV-2 or influenza * Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization * In the Investigator's op...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Zelicapavir is an investigational small molecule antiviral being developed by Enanta Pharmaceuticals, Inc. for the treatment of respiratory syncytial virus, or RSV, infection. It is given as a therapeutic dose and is currently in Phase 2 clinical development. It is not yet approved for any indication.
Zelicapavir is being studied for the treatment of respiratory syncytial virus infection. Development includes a Phase 2 trial in participants from 28 days to 36 months of age who are infected with RSV, and a completed Phase 1 study in healthy adults. It remains investigational and has not been approved for use.
Zelicapavir targets the RSV N-protein, a viral nucleoprotein. By binding this target, the small molecule is designed to interfere with the virus rather than act on a human host protein. This mechanism underlies its development as an antiviral for respiratory syncytial virus infection.
Zelicapavir is being developed by Enanta Pharmaceuticals, Inc., which trades under the ticker ENTA. The company is the sponsor of the clinical program evaluating the drug in respiratory syncytial virus infection, including a Phase 2 trial in young children and a completed Phase 1 study in healthy adults.
Zelicapavir is in Phase 2 clinical development. One Phase 2 trial is currently recruiting, and one Phase 1 trial has been completed. The drug is investigational and has not been approved by the FDA or any other regulatory authority for the treatment of RSV infection.
Zelicapavir has been studied in two trials. NCT07482657 is a recruiting Phase 2 study of zelicapavir in participants aged 28 days to 36 months infected with RSV, conducted in Thailand. NCT06601192 is a completed Phase 1 study evaluating the effects of zelicapavir, also known as EDP-938, on the QTc interval in healthy adults in the United States.
Yes. Zelicapavir is also known as EDP-938, and the two names refer to the same investigational antiviral compound. The completed Phase 1 QTc study used the EDP-938 designation, while current development refers to the drug as zelicapavir. Both names describe the same small molecule targeting the RSV N-protein.